General Information of Drug (ID: DMRABOS)

Drug Name
WX-554 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMRABOS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARRY-162 DM1P6FR Melanoma 2C30 Approved [2]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [3]
BAY 86-9766 DMPW5SB Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
Selumetinib DMC7W6R Neurofibromatosis type 1 LD2D.10 Phase 3 [5]
MSC1936369B DMH1DYU Colorectal cancer 2B91.Z Phase 2 [6]
RO-5126766 DM3U9BY Non-small-cell lung cancer 2C25 Phase 2 [7]
E6201 DMOSL9P Psoriasis vulgaris EA90 Phase 2 [8]
PD-0325901 DM27D4J Breast cancer 2C60-2C65 Phase 2 [2]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
BI-847325 DMY4B6J Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MAPK/ERK kinase kinase (MAP3K) TTROQ37 NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT01581060) Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours. U.S. National Institutes of Health.
2 MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
3 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4 RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47.
5 Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59.
6 Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101.
7 The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
8 E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31.
9 Clinical pipeline report, company report or official report of Roche.
10 doi: 10.1158/1535-7163.TARG-13-B281